Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial

Thomas Althaus, Rachel C Greer, Myo Maung Maung Swe, Joshua Cohen, Ni Ni Tun, James Heaton, Supalert Neduswan, Darannee Intralawan, Nithima Sumpradit, Sabine Dittrich, Zoe Doran, Naomi Waithira, Hlaing Myat Thu, Han Win, Janjira Thaipadungpanit, Prapaporn Silohasin, Mavuto Mukaka, Pieter W Smit, Erin Nutcha Charoenboon, Marco Johannes Haenssngen, Tri Wangrangsimakul, Stuart Blacksell, Direk Limmathurotsakul, Nicholas Day, Frank Smithuis, Yoel Lubell

Summary

Background In southeast Asia, antibiotic prescription in febrile patients attending primary care is common, and a probable contributor to the high burden of antimicrobial resistance. The objective of this trial was to explore whether C-reactive protein (CRP) testing at point of care could rationalise antibiotic prescription in primary care, comparing two proposed thresholds to classify CRP concentrations as low or high to guide antibiotic treatment.

Methods We did a multicentre, open-label, randomised, controlled trial in participants aged at least 1 year with a documented fever or a chief complaint of fever (regardless of previous antibiotic intake and comorbidities other than malignancies) recruited from six public primary care units in Thailand and three primary care clinics and one outpatient department in Myanmar. Individuals were randomly assigned using a computer-based randomisation system at a ratio of 1:1:1 to either the control group or one of two CRP testing groups, which used thresholds of 20 mg/L (group A) or 40 mg/L CRP (group B) to guide antibiotic prescription. Health-care providers were masked to allocation between the two intervention groups but not to the control group. The primary outcome was the prescription of any antibiotic from day 0 to day 5 and the proportion of patients who were prescribed an antibiotic when CRP concentrations were above and below the 20 mg/L or 40 mg/L thresholds. The primary outcome was analysed in the intention-to-treat and per-protocol populations. The trial is registered with ClinicalTrials.gov, number NCT02758821, and is now completed.

Findings Between June 8, 2016, and Aug 25, 2017, we recruited 2410 patients, of whom 803 patients were randomly assigned to CRP group A, 800 to CRP group B, and 807 to the control group. 598 patients in CRP group A, 593 in CRP group B, and 767 in the control group had follow-up data for both day 5 and day 14 and had been prescribed antibiotics (or not) in accordance with test results (per-protocol population). During the trial, 318 (39%) of 807 patients in the control group were prescribed an antibiotic by day 5, compared with 290 (36%) of 803 patients in CRP group A and 275 (34%) of 800 in CRP group B. The adjusted odds ratio (aOR) of 0·80 (95% CI 0·65–0·98) and risk difference of −5·0 percentage points (95% CI −9·7 to −0·3) between group B and the control group were significant, although lower than anticipated, whereas the reduction in prescribing in group A compared with the control group was not significant (aOR 0·86 [0·70–1·06]; risk difference −3·3 percentage points [−8·0 to 1·4]). Patients with high CRP concentrations in both intervention groups were more likely to be prescribed an antibiotic than in the control group (CRP ≥20 mg/L: group A vs control group, p<0·0001; CRP ≥40 mg/L: group B vs control group, p<0·0001), and those with low CRP concentrations were more likely to have an antibiotic withheld (CRP <20 mg/L: group A vs control group, p<0·0001; CRP <40 mg/L: group B vs control group, p<0·0001). 24 serious adverse events were recorded, consisting of 23 hospital admissions and one death, which occurred in CRP group A. Only one serious adverse event was thought to be possibly related to the study (a hospital admission in CRP group A).

Interpretation In febrile patients attending primary care, testing for CRP at point of care with a threshold of 40 mg/L resulted in a modest but significant reduction in antibiotic prescribing, with patients with high CRP being more likely to be prescribed an antibiotic, and no evidence of a difference in clinical outcomes. This study extends the evidence base from lower-income settings supporting the use of CRP tests to rationalise antibiotic use in primary care patients with an acute febrile illness. A key limitation of this study is the individual rather than cluster randomised study design which might have resulted in contamination between the study groups, reducing the effect size of the intervention.

Funding Wellcome Trust Institutional Strategic Support Fund grant (105605/Z/14/Z) and Foundation for Innovative New Diagnostics (FIN Diagnostics) funding from the Australian Government.

www.thelancet.com/lancetgh Vol 7 January 2019 e119-31
See Comment page e14 Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (T Althaus MD, R C Greer MRCGP, Z Doran SNP, N Waithira MSC, J Thaipadungpanit PhD, P Silohasin PhD, M Mukaka PhD, P W Smit PhD, E N Charoenboon BSc, M J Haenssngen PhD, F Wangrangsimakul MRCP, S Blacksell PhD, D Limmathurotsakul PhD, Prof F Day FRCP, Y Lubell PhD); Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (T Althaus, R C Greer, N Waithira, M Mukaka, M J Haenssngen, F Wangrangsimakul, S Blacksell, D Limmathurotsakul, Prof F Day, F Smithuis PhD, Y Lubell); Myanmar-Oxford Clinical Research Unit, Yangon, Myanmar (M M M Swe MPH, J Cohen MD, N N Tun MD, J Heaton MD); Medical Action Myanmar, Yangon, Myanmar (M M M Swe, J Cohen, N N Tun, J Heaton); Primary Care Department, Chiangrai Prachanukroh Hospital, Chiangrai, Thailand (S Neduswan MD, D Intralawan MD, O S Supradit MD); Foundation for Innovative New Diagnostics, Geneva, Switzerland (S Dittrich PhD); and Department of Medical Research, Yangon, Myanmar (H M Thu PhD, H Win MD)
Introduction
Southeast Asia is a global hub of antimicrobial resistance, which is associated with high morbidity and mortality, and is a probable exporter of antimicrobial resistance through dense travel and agricultural trade networks. With an extensive population reach, primary care could be a major force in the fight against antimicrobial resistance; instead, primary care is a setting in which antibiotic prescription is widespread and poorly regulated. Challenges include high patient throughput, diagnostic uncertainty, patient expectations of treatment, and reluctance to refrain from prescribing when follow-up is challenging. A situational analysis of antimicrobial resistance in southeast Asia reported that in Myanmar 87% of patients with upper respiratory tract infections in primary care received an antibiotic, as did 43% of patients in Thailand. A review of 32 primary care centres in northern Thailand found that 47·6% of patients with a documented fever were prescribed antibiotics.

Fever is a common reason for attending primary care facilities. Although malaria can be readily ruled out with rapid tests, the ubiquitous use of these tests as malaria diagnostics is associated with high morbidity and mortality. In primary care settings to all acutely febrile patients older than 12 months. The study included two intervention groups with antibiotic prescription from 78% in the control group to 64% in the intervention group.

Added value of this study
We extended the evaluation of CRP testing in southeast Asian primary care settings to all acutely febrile patients older than 12 months. The study included two intervention groups with different CRP thresholds indicating the need for antibiotics. The findings suggest that only the higher threshold of 40 mg/L was associated with significant reductions in prescribing compared with the control group, although all three study groups had significantly lower antibiotic prescribing from 78% in the control group to 64% in the intervention group.

Implications of all the available evidence
In primary care settings in southeast Asia where the prevalence of antibiotic prescription is high, CRP testing can be used to inform the management of patients with an acute fever and those with an acute respiratory tract infection.
C-reactive protein (CRP) is an acute-phase biomarker of inflammation. Although increases in CRP concentrations have a variety of causes,16 the utility of CRP in distinguishing between bacterial and viral infections has been shown in stored samples from febrile patients in southeast Asia across diverse settings and populations, including inpatients, outpatients, children, adults, and pregnant women.17,18 These studies concluded that CRP is highly sensitive and moderately specific in identifying bacterial infections. Although research and development for better biomarkers continues, CRP testing is potentially a readily available means of improving prescribing decisions as a plethora of CRP point-of-care tests are commercially available,19 with some costing less than US$1·00.20 However, selecting a CRP test for use in routine care requires the identification of optimal thresholds to indicate the need for antibiotic treatment, for which scant evidence is available.

A clinical trial in Vietnamese patients with acute respiratory tract infections in primary care21 found that CRP testing with a threshold of 10 mg/L in children and 20 mg/L in adults reduced antibiotic prescription from 78% to 64% without altering the duration of symptoms. The objective of our clinical trial was to estimate the effect of CRP testing on antibiotic prescription in acutely febrile children and adults attending primary care in Thailand and Myanmar. Previous trials of CRP-guided antibiotic treatment used quantitative readers, which are unlikely to be available in many low-income and middle-income settings. In our trial, health-care providers were notified only as to whether CRP concentrations were low or high with respect to two proposed thresholds—20 mg/L and 40 mg/L. Identifying an optimal threshold for CRP-guided antibiotic treatment could inform the choice of lateral flow devices for use in routine primary care settings.

### Methods

#### Study design and participants

This study was designed as a multicentre, open-label, randomised, controlled trial that compared CRP-guided antibiotic prescription in febrile patients with the standard prescribing practice. The design included two intervention groups with CRP thresholds of 20 mg/L and 40 mg/L to guide antibiotic prescription. These thresholds were selected on the basis of previous literature on CRP concentrations in febrile patients,22,23 particularly studies from southeast Asia,17,18 including a study from Chiangrai, Thailand, that evaluated 20 mg/L and 40 mg/L CRP as candidate thresholds for the identification of bacterial infections (sensitivity of 92% for 20 mg/L and 86% for 40 mg/L).24

In Thailand, primary care units (PCUs) in Chiangrai were selected as study sites for patient recruitment, with the intention of including facilities with high patient turnover while ensuring diversity in terms of the rural or urban environment. Two PCUs were initially included, and four additional sites were later opened because of slow recruitment. In Myanmar, the study was done in three Medical Action Myanmar (MAM) clinics and in one adjacent hospital outpatient department located in the poorest township of Yangon (table 1).25

In terms of policy environment and antimicrobial resistance awareness campaigns, Thailand has been notably active compared with other countries in the region,7 including through its Antibiotic Smart Use (ASU) programme, in place since 2007.26 The programme set a target prescription rate of 20% per month for respiratory infections and acute diarrhoea as part of the key performance indicators for PCUs; this target has been integrated in a pay-for-performance (P4P) policy of the National Health Security Office since 2009. In August, 2016 (during the study), the National Strategic Plan on antimicrobial resistance 2017−21 was endorsed by the cabinet as Thailand’s first national strategy addressing antimicrobial resistance challenges, and the Ministry of Public Health (MOPH) adopted the ASU targets into its Service Plan Policy on Rational Drug Use (RDU).27 Unlike the previous P4P policy that provided financial incentives at the facility level, the RDU Service Plan incentivised higher-level stakeholders in the MOPH to exercise their authority in meeting the antibiotic prescription targets. To achieve this, the MOPH now relies on health

| Sites                     | Location                                               | Health-care provider | Access fees                      | Population                          | Investigations routinely available | Malaria transmission |
|---------------------------|--------------------------------------------------------|----------------------|----------------------------------|-------------------------------------|-----------------------------------|----------------------|
| Chiangrai, Thailand       | Rural and peri-urban settings within a 20 km radius of | Two to three registered nurses per site | Universal health coverage for registered citizens* | Thai community, 35% ethnic minorities | Finger-prick blood glucose test | 0–0·1 cases per 1000 population |
| Hlaing Tha Yar, Myanmar   | Chiangrai city centre                                  |                      | Free                             | Mainly Burmese community            | Rapid test for malaria            | 0–0·1 cases per 1000 population |

*THB30 (US$0·91) were previously charged per visit; this fee is now inconsistently applied.
inspectors to guide and encourage hospitals and PCUs to reduce the unnecessary use of antibiotics. The antimicrobial-resistance policy environment in Myanmar is not well developed, with no relevant policies introduced between 2010 and 2015.7

In addition to the influence of the shifting policy environment, we anticipated a potential for observation bias due to the presence of research staff and a possible contamination effect on prescribing in the control group resulting from exposure to CRP test results in the intervention groups (ie, if healthcare providers observe low frequency of patients with high CRP in the interventions groups, this might affect their prescribing in patients in the control group). Therefore, to understand the prescribing practices in febrile patients in the trial sites before intervention, we did surveys to include retrospective data from January, 2015, to December, 2016, in Thailand, and from November, 2015, to April, 2016, in Myanmar. Further details on the data collection processes for the background surveys are presented in the appendix.

All participants in the trial were aged 1 year or older with a documented fever (defined as a tympanic temperature of >37.5°C according to WHO standards) or a chief complaint of fever (<14 days), regardless of previous antibiotic intake and comorbidities other than malignancies. The exclusion criteria were as follows: infants younger than 1 year; symptoms requiring hospital referral, defined as either impaired consciousness, inability to take oral medication, or convulsions; a positive malaria test; the main complaint being trauma or injury; suspicion of either tuberculosis, urinary tract infection, or local skin or dental abscess or infection; any symptom present for more than 14 days; any bleeding; and an inability to comply with the follow-up visit at day 5. A complete list of all inclusion and exclusion criteria can be found in the protocol summary on ClinicalTrials.gov. All participants (or parents or guardians in the case of children) provided written informed consent. The protocol, informed consent form, and case record forms were reviewed and approved by the Oxford Tropical Research Ethics Committee, the Mahidol University Faculty of Tropical Medicine Ethics Committee, and the Myanmar Department of Medical Research and Chiangrai Provincial Public Health Office Research Ethics Committees.

Study staff explained the trial to potential participants and took their written informed consent to join the study before any study-specific procedures were done. In the case of participants younger than 18 years, a parent or guardian was asked to sign and date the informed consent form (ICF) and the participant was asked to give consent or assent depending on their age and local practice. In the case of illiterate patients or parents or guardians, a witness was asked to sign the ICF to confirm that the participant gave informed verbal consent to participate.

Randomisation and masking

Individuals were randomly assigned at a 1:1:1 ratio to either one of the two intervention groups or the control group and were stratified by country (Thailand and Myanmar) and age group (children and adults, with adulthood defined as age ≥12 years). Computer-based individual randomisation was done at the Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand by the trial statistician (MM) using the ralloc command in Stata version 14. Numbered, sealed, opaque envelopes containing the randomised study group were prepared by the central support team and opened sequentially on site by the study staff after patients were enrolled. Study groups consisted of intervention groups A and B, in which CRP was measured by study staff on site and the result was communicated to the health-care provider as low CRP or high CRP using cutoff thresholds of 20 mg/L (group A) or 40 mg/L (group B), and control group C, in which health-care providers were asked to manage febrile patients as per standard of care.

Health-care providers and patients were masked to allocation between the two intervention groups but by design were aware of allocation to the control group. Research staff could not be masked to patient allocation between all groups.

Procedures

Before patient recruitment, the health-care providers were informed of the utility of CRP to help guide antibiotic prescription, while mitigating the threat of antimicrobial resistance. The information was provided by the study investigators in the local language and dialect, on the basis of previous models developed for CRP-testing-related training,28 and contextualised to the Thai and Myanmar settings. A refresher session was provided around the midpoint of study recruitment. Health-care providers were advised that for febrile patients with no clear danger signs and low CRP concentrations they should refrain from prescribing antibiotics, whereas for patients with high CRP the guidance was to consider prescribing antibiotics on the basis of their clinical judgment. The health-care providers were informed that the test was not of perfect accuracy in its identification of patients requiring antibiotic treatment.

Following randomisation, patients from the intervention groups had a capillary blood sample analysed for CRP on site by the study staff who used a CRP reader (NycoCard II Reader, Axis Shield, Oslo, Norway). A brief educational video on antimicrobial resistance and CRP see https://www.youtube.com/watch?v=hnxsSwbqWOE&feature=youtu.be

For the educational video on antimicrobial resistance and CRP see https://www.youtube.com/watch?v=hnxsSwbqWOE&feature=youtu.be

For a summary of the protocol see https://clinicaltrials.gov/ct2/show/NCT02758821

For a summary of the protocol

See Online for appendix
primary-care health provider who decided whether an antibiotic was required. Demographic and clinical data were recorded by the study staff on a case report form (CRF).

All patients were followed up both at day 5 (allowable range 4–7 days) and day 14 (allowable range 12–16 days) after recruitment by face-to-face appointment with study staff. If patients were unable to attend a follow-up visit in person, a structured telephone interview was done instead. Patients in all three groups were tested for CRP at the second visit (day 5) on site by the study staff to help gauge clinical recovery, and health-care providers were informed if CRP concentrations were equal to or higher than 50 mg/L in children, and equal to or higher than 100 mg/L in adults.

Patients received compensation for their time and travel expenses at enrolment and on each of the follow-up visits if they reattended in person.

Outcomes
The primary outcome was the proportion of patients who were prescribed any antibiotic at the facility from day 0 to day 5 (allowable range 4–7) in each intervention group in total, and the proportion of patients who were prescribed an antibiotic when CRP concentrations were above and below the 20 mg/L or 40 mg/L thresholds. The CRP reading was done in a central lab off-site for the control group and it was performed on site for the intervention groups. The data on prescribing were recorded independently on site and the outcome was assessed centrally. Secondary outcomes included the proportion of patients prescribed an antibiotic from day 0 to day 14 at the health facility. Clinical outcomes included patient self-reported recovery at each follow-up visit, duration and severity of symptoms, frequency of unplanned reconsultation within the 14 days of follow-up, temperature and CRP concentrations at day 5 as objective measures of clinical recovery, and occurrence of serious adverse events, defined as events requiring admission to hospital or death within 14 days of enrolment. Due to the extensive trial outputs, this manuscript reports the primary outcome and key secondary outcomes relating to antibiotic prescribing and clinical recovery. The other
Table 2: Day 0 characteristics comparing control group, group A (20 mg/L CRP threshold), and group B (40 mg/L CRP threshold)

| Clinical characteristics and self-reported symptoms | Control group | CRP group A | CRP group B |
|-----------------------------------------------------|---------------|-------------|-------------|
| Sex                                                  |               |             |             |
| Male                                                 | 204 (51%)     | 209 (52%)   | 204 (51%)   |
| Female                                               | 198 (49%)     | 191 (48%)   | 195 (49%)   |
| Age, median (IQR), years                            | 4 (2–7)       | 4 (2–7)     | 4 (2–7)     |
| ≥30 min to reach the facility                       | 100 (25%)     | 100 (25%)   | 98 (25%)    |
| Presence of comorbidity*                             | 120 (30%)     | 120 (30%)   | 120 (30%)   |
| Symptoms onset, median (IQR), days                  | 2 (1–3)       | 2 (1–3)     | 2 (1–3)     |
| Self-reported antibiotic intake                      | 16 (4%)       | 20 (5%)     | 22 (6%)     |
| Clinical characteristics                            |               |             |             |
| Documented fever (>37.5°C)                          | 200 (50%)     | 203 (51%)   | 223 (56%)   |
| Neurological symptoms†                               | 62 (15%)      | 39 (10%)    | 40 (10%)    |
| Respiratory symptoms‡                                | 126 (31%)     | 315 (79%)   | 327 (82%)   |
| Gastrointestinal tract symptoms§                     | 104 (26%)     | 124 (31%)   | 109 (27%)   |
| Other symptoms¶                                      | 9 (2%)        | 41 (10%)    | 30 (8%)     |

Data are number (%) or median (IQR). CRP=C-reactive protein. *Comorbidities included HIV infection, chronic hepatitis B or C infection, cirrhosis, diabetes, asthma, anaemia, chronic obstructive pulmonary disease, gastritis, congenital heart or kidney disease, alcoholism, dyslipidaemia, glucose-6-phosphate dehydrogenase deficiency, hypertension, rheumatic heart disease, thalassaemia, or thyroid disease. †Neurological symptoms include headache, confusion, dizziness, or hearing loss. ‡Respiratory symptoms include sore throat, dyspnoea, chest pain, runny nose, or cough. §Gastrointestinal symptoms include nausea, vomiting, diarrhoea, or abdominal pain. ¶Other symptoms declared were defined by the presence of fever alone or symptoms other than those present in neurological, respiratory, or gastrointestinal symptoms. Common symptoms in this group included myalgia, arthralgia, jaundice, tiredness, chills, sweating, weight loss, skin eruption, dysuria, or eye redness.

Secondary outcomes of the study—the correlation between CRP results and clinical outcomes on day 5 of follow-up, the impact of CRP testing on antibiotic consumption obtained elsewhere after the first consultation, the attitudes and satisfaction of health-centre staff and patients towards the CRP test, the prevalence of key pathogens in febrile patients in these settings, and the ability of CRP to discriminate between viral and bacterial pathogens—will be reported elsewhere.

Statistical analysis

We expected CRP testing to reduce antibiotic prescriptions by 25% from baseline, but with anticipated contamination between study groups, the sample size was increased to detect a reduction in antibiotic prescription by 20% independently for children and adults in each country. The sample size was adjusted further to account for multiple comparisons between the three study groups on the basis of Bonferroni’s correction. An adjusted significance level (type I error) of 0.017 was used to yield a 5% overall significance level for the three comparisons. Allowing for a projected 15% loss to follow-up required 198 patients per study group, rounded to 200, to give a total of 2400 patients (600 children and 600 adults per country).

The trial was analysed by intention to treat and per protocol (appendix). The per-protocol analysis included patients for whom follow-up data were available on both day 5 and day 14, and to whom health-care providers prescribed antibiotics in accordance with test results; therefore, the effect size in the per-protocol analysis represents the potential effect of the tests under full compliance.

Differences in primary and secondary outcomes were analysed overall and in the four predefined subgroups of country and age category. Descriptive statistics for continuous variables with normal distribution used means and SD and medians with IQR for non-normally distributed continuous variables. Comparison between groups used t tests for normally distributed variables, the Mann-Whitney test for non-normally distributed variables, and χ² test for categorical variables.

Primary and secondary outcomes between each of the intervention groups and the control group were compared using a logistic regression model; health facilities were considered to have a random effect on the primary outcome.

The difference in the number of prescriptions of various broad-spectrum antibiotics was also compared, including ceftriaxone, cefixime, ciprofloxacin, levoflaxacin, azithromycin, and amoxicillin with clavulanic acid. The exhaustive list of antibiotics prescribed at the facilities is provided in the appendix. This analysis was not prespecified in the study protocol.

We generated Kaplan-Meier curves to visualise time to clinical recovery on the basis of the patient declaration, with a corresponding p value using a log-rank test for survival curves. We used a Cox regression model to quantify the difference in clinical outcomes
between intervention and control groups calculating the adjusted hazard ratios (HRs), with age stratum and country as fixed effects and health-care centres as a Gaussian random effect. The 95% CIs have been provided where appropriate. Data analyses were done with Stata version 15. The Clinical Trial Support Group at the Mahidol Oxford Tropical Medicine Research Unit did two monitoring visits to each site to ensure the integrity of the data; the first visit took place after 200 children and adults were enrolled in each country, and a second at the end of the study recruitment. This trial is registered with ClinicalTrials.gov, number NCT02758821.

Role of the funding source
The funders had no role in study design, data collection, data interpretation, or writing of the manuscript. The corresponding author (YL) had full access to all the data in the study and had the final responsibility to submit for publication.

Results
A total of 4116 patients were assessed for eligibility, of whom 2410 children and adults with a documented fever or a history of fever were prospectively recruited between June 8, 2016, and Aug 25, 2017, across ten facilities (figure 1). 803 patients were randomly assigned to CRP group A, 800 to CRP group B, and 807 to the control group (the intention-to-treat population). 598 patients in CRP group A, 593 in CRP group B, and 767 in the control group had follow-up data for both day 5 and day 14 and had been prescribed antibiotics in accordance with test results, so were included in the per-protocol population. Patient characteristics in the control group and the two intervention groups were similar at day 0 (table 2).

Patients attended the facilities within a median of 2·5 days (IQR 1–4) after onset of symptoms. Clinically, respiratory symptoms were the most common presentation, followed by gastrointestinal and neurological symptoms (stratified results per country and age category are presented in the appendix).

Figure 2: Background antibiotic prescription in Thailand and Myanmar
OPD=outpatient department. *Estimated prescriptions in patients for whom clinical data on febrile status were available. †Estimated prescriptions in all patients on non-routine visits (febrile status unknown).
290 (36%) of 803 patients were prescribed an antibiotic from day 0 to day 5, a non-significant difference compared with control group (risk difference –3·3 percentage points, 95% CI –8·0 to 1·4; aOR 0·86, 95% CI 0·70 to 1·06). The per-protocol analysis (appendix) showed a –20·4 percentage point difference (95% CI –25 to –15·7) in antibiotic prescription for the primary outcome in group B compared with the control group (aOR 0·35, 95% CI 0·27 to 0·45) and a –12·3 percentage point difference (–17·3 to –7·4) in group A compared with the control group (aOR 0·56, 0·44 to 0·71).

The trial primary outcome also included antibiotic prescription in relation to the CRP thresholds, with a higher proportion of patients with elevated CRP concentrations being prescribed an antibiotic in the intervention groups than in the control group (CRP ≥20 mg/L: 153 [74%] of 206 patients in group A vs 103 [48%] of 214 in the control group, p<0·0001; CRP ≥40 mg/L: 92 [78%] of 118 patients in group B vs 51 [48%] of 107 in the control group, p<0·0001; figure 3). Conversely, in patients with low CRP concentrations, antibiotic prescription was lower in the intervention groups than in the control group (CRP <20 mg/L: 119 [20%] of 595 patients in group A vs 134 [30%] of 445 in the control group, p<0·0001; CRP <40 mg/L: 153 [22%] of 682 patients in group B vs 186 [34%] of 552 in the control group, p<0·0001). Considering a threshold of 20 mg/L CRP as indicative of requiring antibiotics, 414 (63%) of 659 patients in the control group had an antibiotic correctly prescribed or

| Control group | CRP group A | Risk difference (95% CI) | aOR* (95% CI) | CRP group B | Risk difference (95% CI) | aOR* (95% CI) |
|---------------|-------------|--------------------------|---------------|-------------|--------------------------|---------------|
| All age groups in Thailand and Myanmar | 807 | 803 | 800 | 297 (36·8%) | 269 (33·5%) | –3·3 (–8·0 to 1·4) | 0·86 (0·70 to 1·06) | 245 (30·6%) | –6·2 (–10·8 to –1·6) | 0·75 (0·60 to 0·92) |
| Number of participants | 807 | 803 | 800 | 297 (36·8%) | 269 (33·5%) | –3·3 (–8·0 to 1·4) | 0·86 (0·70 to 1·06) | 245 (30·6%) | –6·2 (–10·8 to –1·6) | 0·75 (0·60 to 0·92) |
| Between day 0 and day 5 | 318 (39·4%) | 290 (36·1%) | –3·3 (–8·0 to 1·4) | 0·86 (0·70 to 1·06) | 275 (34·4%) | –5·0 (–9·7 to –0·3) | 0·80 (0·65 to 0·98) |
| Between day 0 and day 14 | 323 (40·0%) | 292 (36·4%) | –3·7 (–8·4 to 1·1) | 0·85 (0·69 to 1·04) | 279 (34·9%) | –5·2 (–10·0 to –0·4) | 0·79 (0·64 to 0·98) |
| Patients aged <12 years in Thailand | 195 | 194 | 193 | 64 (32·8%) | 56 (28·9%) | –4·0 (–13·1 to 5·2) | 0·83 (0·53 to 1·28) | 49 (25·4%) | –7·4 (–16·4 to 1·6) | 0·68 (0·43 to 1·08) |
| Number of participants | 195 | 194 | 193 | 64 (32·8%) | 56 (28·9%) | –4·0 (–13·1 to 5·2) | 0·83 (0·53 to 1·28) | 49 (25·4%) | –7·4 (–16·4 to 1·6) | 0·68 (0·43 to 1·08) |
| Between day 0 and day 5 | 68 (34·9%) | 61 (31·4%) | –3·4 (–12·8 to 5·9) | 0·85 (0·55 to 1·31) | 52 (26·9%) | –7·9 (–17·1 to 1·2) | 0·68 (0·43 to 1·06) |
| Between day 0 and day 14 | 69 (35·4%) | 61 (31·4%) | –3·9 (–13·3 to 5·4) | 0·83 (0·54 to 1·28) | 52 (26·9%) | –8·4 (–17·6 to 0·7) | 0·66 (0·42 to 1·03) |
| Patients aged ≥12 years in Thailand | 201 | 200 | 199 | 63 (31·3%) | 57 (28·5%) | –2·8 (–11·8 to 6·1) | 0·86 (0·56 to 1·34) | 65 (32·7%) | 1·3 (–7·8 to 10·5) | 1·06 (0·69 to 1·63) |
| Number of participants | 201 | 200 | 199 | 63 (31·3%) | 57 (28·5%) | –2·8 (–11·8 to 6·1) | 0·86 (0·56 to 1·34) | 65 (32·7%) | 1·3 (–7·8 to 10·5) | 1·06 (0·69 to 1·63) |
| Between day 0 and day 5 | 64 (31·8%) | 60 (30·0%) | –1·8 (–10·9 to 7·2) | 0·91 (0·59 to 1·40) | 68 (34·2%) | 2·3 (–6·9 to 11·5) | 1·12 (0·73 to 1·71) |
| Between day 0 and day 14 | 64 (31·8%) | 60 (30·0%) | –1·8 (–10·9 to 7·2) | 0·91 (0·59 to 1·40) | 69 (34·7%) | 2·8 (–6·4 to 12·1) | 1·14 (0·74 to 1·75) |
| Patients aged ≥12 years in Myanmar | 204 | 203 | 202 | 78 (37·7%) | 77 (37·4%) | –0·3 (–9·6 to 9·0) | 0·99 (0·66 to 1·48) | 65 (31·6%) | –6·1 (–15·1 to 3·0) | 0·76 (0·50 to 1·15) |
| Number of participants | 204 | 203 | 202 | 78 (37·7%) | 77 (37·4%) | –0·3 (–9·6 to 9·0) | 0·99 (0·66 to 1·48) | 65 (31·6%) | –6·1 (–15·1 to 3·0) | 0·76 (0·50 to 1·15) |
| Between day 0 and day 5 | 87 (42·0%) | 84 (40·8%) | –1·3 (–10·8 to 8·3) | 0·95 (0·64 to 1·41) | 79 (38·4%) | –3·7 (–13·1 to 5·8) | 0·86 (0·57 to 1·29) |
| Between day 0 and day 14 | 88 (42·5%) | 86 (41·8%) | –0·8 (–10·3 to 8·8) | 0·97 (0·66 to 1·44) | 82 (39·8%) | –2·7 (–12·2 to 6·8) | 0·90 (0·60 to 1·34) |

The prescription of antibiotics from day 0 to day 5 is the primary outcome. Unadjusted odds ratios are presented in the appendix. Data are number or number (%) unless otherwise stated. aOR=adjusted odds ratio. CRP=C-reactive protein. *aORs were adjusted by site as a random effect.

Table 3: Antibiotic prescription in the control group, group A (20 mg/L CRP threshold), and group B (40 mg/L CRP threshold)

Figure 3: Antibiotic prescription on day 0 in relation to the CRP thresholds in each of the intervention groups for all age categories and countries

Error bars represent 95% CI. CRP=C-reactive protein.
withheld, as compared with 632 (79%) of 801 in group A. Similarly, assuming a threshold of 40 mg/L as indicative of the need for an antibiotic, 417 (63%) of 659 in the control group had an antibiotic appropriately prescribed whereas this reduction was only significant on day 0 in group A (aOR 0·60, 95% CI 0·38–0·96).

We observed no differences in the prevalence of recovery as defined by patient declaration at day 5 or day 14 of follow-up between the study groups, with 495 (65%) of 764 at day 5 and 718 (94%) of 760 at day 14 in the 20 mg/L CRP group reporting recovery compared with 488 (63%) of 769 at day 5 and 733 (94%) of 779 at day 14 in the 40 mg/L CRP group, and 491 (64%) of 767 at day 5 and 738 (96%) of 772 at day 14 in the control group (appendix). We present a comparison of the time-to-event curves for recovery between groups A and B and the control group (figure 4). The corresponding log-rank test and HRs in group A and group B were non-significant. Similarly, no differences were found in these outcomes in the per-protocol analysis (appendix).

In cases of persistent illness at day 5 and day 14 of follow-up, the median symptom severity score corresponded to the mildest grade (ie, a severity score of 1 in a scale ranging from 1 to 4) and did not differ across the groups (appendix). The proportion of patients who attended unscheduled visits was 16 (2%) of 807 in the control group, 13 (2%) of 803 in group A, and 22 (3%) of 800 in group B with no significant difference between groups. CRP on day 5 was sufficiently elevated above the predefined threshold to notify health-care providers (50 mg/L in children and 100 mg/L in adults) in

| Neurological presentation | Control group (n=807) | CRP group A (n=803) | Risk difference (95% CI) | aOR* (95% CI) | CRP group B (n=800) | Risk difference (95% CI) | aOR* (95% CI) |
|---------------------------|----------------------|---------------------|------------------------|---------------|---------------------|------------------------|---------------|
| Number of participants    | 210                  | 195                 | -                      | -             | 195                 | -                      | -             |
| On day 0                  | 83 (40%)             | 71 (36%)            | -3·1% (-12·6 to 6·3)   | 0·85 (0·56 to 1·29) | 65 (33%)            | -6·2% (-15·3 to 2·9)   | 0·71 (0·46 to 1·10) |
| Between day 0 and day 5   | 90 (43%)             | 78 (40%)            | -3·8% (-13·4 to 5·8)   | 0·84 (0·55 to 1·26) | 65 (33%)            | -8·4% (-17·9 to 1·1)   | 0·65 (0·43 to 1·00) |
| Between day 0 and day 14  | 92 (44%)             | 78 (40%)            | -3·8% (-13·4 to 5·8)   | 0·84 (0·55 to 1·26) | 65 (33%)            | -8·4% (-17·9 to 1·1)   | 0·65 (0·43 to 1·00) |

Data are number or number (%) unless otherwise stated. The prescription of antibiotics from day 0 to day 5 is the primary outcome. aOR=adjusted odds ratio. CRP=C-reactive protein. *aORs were adjusted by site as a random effect.

Table 4: Subgroup analysis for antibiotic prescription

---

www.thelancet.com/lancetgh Vol 7 January 2019 e127
eight (1%) of 706 patients in the control group, eight (1%) of 706 in CRP group A, and six (1%) of 726 in CRP group B with no significant difference between study groups. 74 (3%) of 2150 patients had a tympanic temperature of more than 37·5°C on day 5 and 31 (2%) of 1951 on day 14 with no significant differences between the study groups. Further details on clinical outcomes by age and country are presented in the appendix.

Among the 2410 study participants, 24 severe adverse events occurred (23 hospital admissions and one death), with ten (1%) severe adverse events in group A, 11 (1%) in group B, and three (<1%) in the control group (p=0·064 for group A and p=0·043 for group B compared with the control group). Among these 24 severe adverse events, 23 were classified as being not related to the study (nine in group A, 11 in group B, and three in the control group), and one was classified as being possibly related, occurring in a woman aged 25 years who had an abdominal complaint and fever with low CRP (randomly assigned to group A), initially diagnosed by the attending health-care provider as a hypersensitivity reaction, and no antibiotic was prescribed. During admission the woman was diagnosed with mesenteric lymphadenitis, and was prescribed antibiotics and discharged alive. No microbiological investigations were done at the hospital. One death occurred during the study, which was that of a man aged 78 years who was randomly assigned to group A and had chronic obstructive pulmonary disease and heart disease. The man’s CRP concentration was high, and antibiotics were prescribed on day 0; this severe adverse event was classified as not related to the study.

### Discussion

In this trial we have shown that, in primary care in southeast Asia, CRP testing with a threshold of 40 mg/L reduced antibiotic prescription in patients with a fever with no evidence of a difference in clinical recovery. Reductions in prescription were greater in patients with a documented fever, in those with respiratory presentation, and for broad-spectrum antibiotics. In addition to reducing antibiotic prescription, patients in the intervention groups with high CRP concentrations were more likely to be prescribed an antibiotic and those with low CRP concentrations were more likely to have antibiotics withheld than patients in the control group. These effects were more pronounced within group B, in which a higher threshold of 40 mg/L was used, whereas the differences between group A and the control group were of lesser magnitude and mostly not of statistical significance.

The effect size was smaller than anticipated when comparing the intervention and control groups but the difference in the proportion of patients who were prescribed antibiotics seemed to be much larger when comparing our trial data with our retrospective 2015–16 antibiotic prescription data; whether these reductions in prescribing, small or large, can have a real effect on mitigating drug pressure and the development of antimicrobial resistance is difficult to establish. With the majority of human antibiotic consumption occurring in the community and in patients with fevers and respiratory illness in particular, even small reductions in prescription could imply a large alleviation of drug pressure. Further modelling and cost-effectiveness analyses are required to explore whether these reductions and the cost of achieving them are warranted from an economic and global health perspective. A modelling analysis conservatively estimated that in the Thai context the economic costs of antimicrobial resistance per course of broad-spectrum penicillins (widely used in this study) was approximately $10. A reduction of just 10 percentage points from baseline with the use of a CRP test costing $1 could therefore be considered cost beneficial from a societal perspective.29
and the majority of patients in the trial had low CRP concentrations on day 0 (<20 mg/L in 72% of patients and <40 mg/L in 86%; appendix). As CRP is known to be of high sensitivity but only moderate specificity in the detection of bacterial infections, the higher threshold of 40 mg/L is likely to be appropriate for these settings, and stricter adherence to test results at this threshold would generate larger reductions in prescribing, as shown in the per-protocol analysis (>20% reduction for the primary outcome between group B and the control group; appendix). This reduction in prescribing might be achieved in scale-up programmes driven by local health authorities supported by high-level policy change. Integrating CRP testing into clinical guidelines could also enhance prescribers’ confidence, as might electronic user-friendly algorithms that strengthen the consistency of fever management. Clinical and communication skills training could also enhance compliance with these algorithms.

A systematic review of studies on biomarker testing in febrile children in emergency departments, all in high-income settings, concluded that CRP testing could be diagnostically useful, recommending a low threshold of 5 mg/L to rule out serious infection and a threshold of 80 mg/L to suggest the presence of serious infection. A cluster randomised trial in Belgium concluded that CRP testing in primary care should be targeted at children at high risk of severe infection after clinical assessment. This targeting could also avoid medicalisation of minor ailments. A multicountry European study showed enhanced pneumonia prediction in patients in primary care presenting with acute cough when CRP testing was added to a clinical algorithm based on symptoms alone. This risk stratification relied on the availability of experienced clinicians. In Thailand, which has a well-developed public health sector, such strategies could be relevant, with adequate supervision of health-care providers’ clinical skills combined with clear referral and follow-up systems to ensure patient safety. The low number of prescriptions in the Thai control group suggests that reductions in prescribing could be attained with better training, supervision, or financial incentives, with CRP testing offering modest additional gains.

The evidence base for the evaluation of the effect of CRP-guided treatment from lower-income settings is small, and, because of particular comorbidities and pathogen exposure in lower-income countries in the tropics, data from high-income (non-tropical) settings are not easily comparable. A Tanzanian-based clinical trial on fever management showed that a host of interventions including CRP and procalcitonin tests, pulse oximetry, haemoglobin tests, and an electronic patient management algorithm, were able in combination to reduce prescribing from 95% to approximately 10% of patients. The costs and benefits of implementing a more comprehensive bundle of interventions need to be weighed against the lower costs and benefits of CRP testing alone. A trial using only CRP tests in acute respiratory tract infections in primary care in Vietnam reported a 20% reduction in prescribing on first attendance.

Data for the retrospective survey in Thailand were obtained from a search of routinely collected electronic medical records, making the verification of the data challenging; however, CRF data from a subsample of patients included in this retrospective survey were compared with their respective routine medical records and were found to be consistent. The retrospectively collected 2015–16 antibiotic prescription data for the MAM sites did not include patients’ febrile status and only had the total number of prescriptions in the corresponding months, therefore our retrospectively collected prescription data are likely to underestimate the actual proportion of patients with a suspected infection who were prescribed an antibiotic. Despite these limitations, the retrospective surveys indicate much higher prescription rates than those observed in the research environment.

The primary outcome of the study, antibiotic prescription in response to CRP testing, is behavioural rather than biological, and therefore results need careful interpretation that considers contextual factors such as the broader policy environment and study design biases. In Thailand, reductions in prescribing were probably driven by policy changes implemented during the study period. Although our study adopted a mixed-methods approach that included social research components to better understand these contextual factors, disentangling and quantifying their relative contribution is challenging. The addition of a diagnostic tool did, however, enable further reductions in prescribing, supporting a multifaceted approach.

The reduction in prescribing in all study groups could also be explained by the Hawthorne effect because of the presence of research staff on site who were carrying out the CRP tests and monitoring prescribing. Prescribing in the control group might also have been affected by contamination (because of recognition that most patients have low CRP concentrations and do not require an antibiotic), therefore underestimating the effect that CRP testing could have in a routine care environment. The ideal study design would therefore have been a cluster randomised trial without the presence of research staff on site who were carrying out the CRP tests and monitoring prescribing. Prescribing in the control group might also have been affected by contamination (because of recognition that most patients have low CRP concentrations and do not require an antibiotic), therefore underestimating the effect that CRP testing could have in a routine care environment. The ideal study design would therefore have been a cluster randomised trial without the presence of research staff on site and with the tests being performed by routine health-care providers.

Our study was powered to detect a difference in antibiotic prescription, rather than clinical outcomes. The reason we chose this endpoint was that CRP is already widely used in hospital settings in the management of febrile patients and has been shown to be highly sensitive in detecting bacterial infections in the region. In the context of primary care and with the exclusion of patients presenting with clear danger signs, we expected very few severe outcomes, as was indeed the
case. Although powering the study to detect differences in such rare events would not be feasible, the study recruited more than 2400 patients with high follow-up and no evidence of a difference between the groups was detected in the extensive measures of clinical outcome. Furthermore, in our study CRP tests were provided as an aid to health-care providers’ clinical judgment, with only soft recommendations on how the tests could inform their prescribing decisions.

CRP testing in a southeast Asian primary care setting has previously been shown to reduce antibiotic prescribing in patients with respiratory tract infection and our trial extends this evidence base to those with a fever. Together, these patients represent the majority of acute primary care attendees. The fact that the proportion of patients in the control group who were prescribed an antibiotic seemed to be lower than our retrospectively collected data on antibiotic prescribing in the region indicates that substantial progress is attainable through other mechanisms, with CRP testing using a threshold of 40 mg/L bringing a modest incremental effect. These findings correspond with previous studies recommending a restricted use of CRP tests in high-risk groups, including children with high fever. This restricted use might well be viable in facilities staffed by experienced clinicians and where patient follow-up is feasible. In more peripheral settings, with minimally trained health-care providers and where follow-up of patients is a challenge, testing all febrile patients could provide an additional safety net, ensuring that patients requiring treatment are identified as such. In these settings, low-cost lateral flow devices are most likely to be relevant, for which we provide further evidence on the optimal threshold. Introduction of the tests should be planned in consideration of the local policy environment and accompanied by training for health-care providers and education for patients on the ability of CRP testing to identify when antibiotic treatment is required, and the need for better targeting of antibiotics in the fight against antimicrobial resistance.

**Contributors**

TA, RCG, MMMS, NS, SD, JT, ENC, MJH, TW, DL, ND, FS, and YL contributed to the literature review. The study was designed by TA, RCG, TW, ND, FS, SN, DI, SB, ZD, NW, HMT, HW, PWS, and YL. Data collection was done by MMMS, JC, NNT, JH, PS, ENC, PWS, and MJH, data analysis by TA, RCG, MMMS, MM, TW, and YL, and data interpretation by TA, RCG, MMMS, SD, MM, ENC, MJH, TW, DL, FS, and YL. Figures were created by TA, RCG, MMMS, DI, and YL. The manuscript was written by TA, RCG, and YL. All authors reviewed the manuscript, added appropriate revisions, agreed to submission for publication, and approved the final version. TA and YL are guarantors.

**Declaration of interests**

We declare no competing interests.

**Acknowledgments**

We thank all trial participants, including patients, carers, and health-care providers for taking part in the study. We are very grateful to the study nurses and clinicians and to the Clinical Trial Support Group at Mahidol-Oxford Tropical Medicine Research Unit for ensuring the successful completion of the trial. We thank Heinman Wertheim, Arjen Dondorp, Paul Turner, Claudia Turner, Christopher Parry, James Watson, and Paul Newton for guidance on the study design; Clare Ling, Toni Whisler, Jonaz Winchell, Maureen Diaz, Anupai Tangmantisitchitcharna, Arerat Thaiprayakhong, Nuttapon Pinrithong, and Kyaw Soe for laboratory support, and Elizabeth Ashley, Jeroen Bok, and Khin Yupar Soe for their assistance in study site coordination. This study was supported by a Wellcome Trust Institutional Strategic Support Fund grant (05605/Z/14/Z) and with Foundation for Innovative New Diagnostics funding from the Australian Government.

**References**

1. Panda S, Swaminathan S, Hyder KA, et al. Drug resistance in malaria, tuberculosis, and HIV in South East Asia: biology, programme, and policy considerations. *BMJ* 2017; 358: j3545.
2. Zellweger RM, Carrique-Mas J, Limmuthurosatkul D, et al. A current perspective on antimicrobial resistance in Southeast Asia. *J Antimicrob Chemother* 2017; 72: 296–327.
3. Martinez-Gonzalez NA, Coenen S, Plate A, et al. The impact of interventions to improve the quality of prescribing and use of antibiotics in primary care patients with respiratory tract infections: a systematic review protocol. *BMJ Open* 2017; 7: e016253.
4. Dempsey PP, Businger AC, Whaley LE, et al. Primary care clinicians’ perceptions about antibiotic prescribing for acute bronchitis: a qualitative study. *BMC Fam Pract* 2014; 15: 194.
5. Hongoro C, McPake B. How to bridge the gap in human resources for health. *Lancet* 2004; 364: 1451–56.
6. Mendelson M, Rettingen JA, Gopinathan U, et al. Maximising access to appropriate human antimicrobial use in low-income and middle-income countries. *Lancet* 2016; 387: 188–98.
7. Holloway KA, Batamabangane G, Puri M, et al. Antibiotic use in South East Asia and policies to promote appropriate use: reports from country situational analyses. *BMJ* 2017; 358: j2291.
8. Greer RC, Intralawan D, Mukaka M, et al. Retrospective review of the management of acute infections and the indications for antibiotic prescription in primary care in northern Thailand. *BMJ Open* 2018; 8: e022250.
9. Hopkins H, Buxvoort KJ, Cairns ME, et al. Impact of introduction of rapid diagnostic tests for malaria on antibiotic prescribing: analysis of observational and randomised studies in public and private healthcare settings. *BMJ* 2017; 356: i054.
10. Chihng K, Carter MJ, Emray K, et al. A prospective study of the causes of febrile illness requiring hospitalization in children in Cambodia. *PLoS One* 2013; 8: e60634.
11. Maysay M, Castonguay-Vanier J, Chansamouth V, et al. Causes of non-malarial fever in Laos: a prospective study. *Lancet Glob Health* 2013; 1: e66–54.
12. Network SAIDEC. Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study. *Lancet Glob Health* 2017; 5: e157–67.
13. O’Neill J. Rapid diagnostics: stopping unnecessary use of antibiotics. Review on antimicrobial resistance. 2015. https://amr-review.org/sites/default/files/Paper-Rapid-Diagnostics-Stopping-Unnecessary-Prescription-Low-Res.pdf (accessed Nov 21, 2018).
14. Dittrich S, Tadesse BT, Moussy F, et al. Target product profile for a current perspective on antimicrobial resistance in Southeast Asia. *BMC Infect Dis* 2017; 11: e016721.
15. Kapasi AJ, Dittrich S, Gonzalez IJ, et al. Host biomarkers for distinguishing bacterial from non-bacterial causes of acute febrile illness: a comprehensive review. *PLoS One* 2016; 11: e0160278.
16. Landry A, Docherty P, Ouellette S, et al. Causes and outcomes of markedly elevated C-reactive protein levels. *Can Fam Physician* 2017; 63: e136–23.
17. Chansamouth V, Thammasack S, Phetouvanh R, et al. The aetiologies and impact of fever in pregnant inpatients in Vientiane, Laos. *PLoS Negl Trop Dis* 2016; 10: e004577.
18. Lubell Y, Blacksell S, Dunachie S, et al. Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in southeast Asia. *BMC Infect Dis* 2015; 15: 511.
19. Phommasonke K, Althaus T, Souvanthong P, et al. Accuracy of commercially available c-reactive protein rapid tests in the context of undifferentiated fevers in rural Laos. *BMC Infect Dis* 2016; 16: 61.
20 Foundation for Innovative New Diagnostics. CRP landscape. https://www.finddx.org/wp-content/uploads/2018/03/CRP_List_2018_02_26.pdf (accessed Nov 21, 2018).

21 Do NT, Tu NT, Tran NT, et al. Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary health care: a randomised controlled trial. Lancet Glob Health 2016; 4: e633–41.

22 Ashkenazi-Hoffnung L, Oved K, Navon R, et al. A host-protein signature is superior to other biomarkers for differentiating between bacterial and viral disease in patients with respiratory infection and fever without source: a prospective observational study. Eur J Clin Microbiol Infect Dis 2018; 37: 1361–71.

23 Page AL, de Rekeneire N, Sayadi S, et al. Diagnostic and prognostic value of procalcitonin and C-reactive protein in malnourished children. Pediatr 2014; 133: e163–70.

24 Wangsangsinmakul T, Alhauz T, Mukaka M, et al. Causes of acute undifferentiated fever and the utility of biomarkers in Chiangrai, northern Thailand. PloS Negl Trop Dis 2018; 12: e0006477.

25 Htwe T, Oo WM, Iwin N, et al. Poverty among households living in slum area of Hlaing Tharyar Township, Yangon City, Myanmar. Int J Res Med Sci 2017; 5: 2497–501.

26 Sumpradit N, Chongtrakul P, Anuwong K, et al. Antibiotics smart use: a workable model for promoting the rational use of medicines in Thailand. Bull World Health Organ 2012; 90: 905–13.

27 Sumpradit N, Wongkongkathep S, Poopolkup S, et al. New chapter in tackling antimicrobial resistance in Thailand. BMJ 2017; 358: j3415.

28 Cals JW, Chappin FH, Hopstaken RM, et al. C-reactive protein point-of-care testing for lower respiratory tract infections: a qualitative evaluation of experiences by GPs. Fam Pract 2010; 27: 212–18.

29 Shrestha P, Cooper BS, Coats J, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control 2018; 7: 98.

30 Keitel K, Kagoro F, Samaka J, et al. A novel electronic algorithm using host biomarker point-of-care tests for the management of febrile illnesses in Tanzanian children (e-POCT): a randomized, controlled non-inferiority trial. PloS Med 2017; 14: e1002411.

31 Cals JW, Butler CC, Hopstaken RM, et al. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009; 338: b1374.

32 Van den Bruel A, Thompson MJ, Haj-Hassan T, et al. Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review. BMJ 2011; 342: d3082.

33 Verbakel JY, Lemiengre MB, De Burghgraeve T, et al. Should all acutely ill children in primary care be tested with point-of-care CRP: a cluster randomised trial. BMC Med 2016; 14: 131.

34 van Vugt SF, Broekhuizen BD, Lammens C, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346: f2450.

35 Zaw YK, Charoenboon N, Hønsensg Mj, et al. A comparison of patients’ local conceptions of illness and medicines in the context of c-reactive protein biomarker testing in Chiang Rai and Yangon. Am J Trop Med Hyg 2018; 98: 1661–70.